Dr. Njar has over 38 years of demonstrated accomplishment as a medicinal chemist and oncopharmacologist in academia at several universities, including 23 years with University of Maryland School of Medicine, Baltimore, MD, USA. He has >120 scientific publications, over 35 issued patents and 30+ pending patents; H-Index: 43; citations: 10,571. He has a Ph.D. in Chemistry (University College. London, UK) and completed a Postdoctoral Fellowship at the Worcester Foundation for Experimental biology, Shrewsbury, MA, USA. He is Currently Professor of Medicinal Chemistry and Pharmacology in the Department of Pharmacology at the University of Maryland School of Medicine, Baltimore and Head, Medicinal Chemistry Section, Center for Biomolecular Therapeutics (CBT); Institute for Bioscience and Biotechnology Research (IBBR). He is the Lead Inventor of a drug candidate, galeterone (originally code named VN/124-1), which advanced to Phase III clinical trials in patients with metastatic castration resistant prostate cancer (licensed by UMB to Tokai Pharmaceutical Inc., Boston, MA, USA). Galeterone was recently licensed to Education Scientific LLC (ESL), who is continuing its clinical development. Dr. Njar co-founded Isoprene Pharmaceuticals Inc (IPI) in 2018, a cancer therapeutic company developing novel small molecules for the treatment of cancer.

Back